LENSAR (NASDAQ:LNSR) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

LENSAR (NASDAQ:LNSR) released its earnings results on Tuesday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02), FiscalAI reports. The company had revenue of $16.03 million for the quarter, compared to the consensus estimate of $20.30 million.

Here are the key takeaways from LENSAR’s conference call:

• The planned acquisition by Alcon was mutually terminated after FTC opposition; LENSAR regained the $10 million escrow deposit and will continue as an independent company.
• Management says the ALLY Robotic Cataract Laser was validated by the acquisition interest and achieved ~200 installed systems (up ~48% year-over-year) and U.S. market share growth to 23.4%, supporting competitive strength.
• Recurring procedure revenue strengthened—2025 recurring revenue rose ~15% to $46.3 million (Q4 annualized >$50M) and comprised ~79% of Q4 revenue, providing higher-margin, predictable cash flow.
• International distributor uncertainty tied to the acquisition caused a meaningful slowdown in outside‑U.S. system sales (only one OUS sale in Q4), and management expects several quarters to rebuild OUS momentum.
• Despite ~$17.1M of merger-related charges and Q4 revenue of $16 million (down 4% YoY), LENSAR reported positive adjusted EBITDA for 2025, forecasts 46–49% gross margin in 2026, and expects ≤10% growth in cash-based operating expenses as it reactivates commercial efforts.

LENSAR Stock Up 1.5%

Shares of NASDAQ:LNSR opened at $5.96 on Wednesday. LENSAR has a twelve month low of $5.35 and a twelve month high of $14.31. The stock’s 50 day moving average is $10.70 and its 200-day moving average is $11.26. The firm has a market capitalization of $71.16 million, a price-to-earnings ratio of -1.36 and a beta of 0.66.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new position in shares of LENSAR during the first quarter valued at about $546,000. Acadian Asset Management LLC acquired a new stake in shares of LENSAR in the 1st quarter worth about $257,000. Geode Capital Management LLC raised its holdings in shares of LENSAR by 103.9% in the 2nd quarter. Geode Capital Management LLC now owns 219,373 shares of the company’s stock worth $2,890,000 after acquiring an additional 111,802 shares during the last quarter. JPMorgan Chase & Co. lifted its position in LENSAR by 584.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company’s stock valued at $62,000 after acquiring an additional 3,991 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new position in LENSAR in the 2nd quarter valued at about $105,000. Institutional investors and hedge funds own 40.15% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. BTIG Research raised shares of LENSAR from a “neutral” rating to a “buy” rating in a research note on Tuesday, March 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of LENSAR in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.